We first described our algorithm in January 2025 (preprint) with the journal-submitted version currently under its second revision, and have since presented our most recent results at various conferences, such as ASMS in June 2025 (methods description), MSACL in September 2025 (operational considerations), and HUPO in November 2025 (a Parkinson's biomarker project ).

This last poster may the most relevant and interesting, not only because it is a reflection of the ultimate goal of our company (i.e., we wish to separate study conditions), but also because we were able to do so on (1) a dataset that was generated on relatively old technology (i.e., the MS used, a Thermo Exploris 480, was first introduced in June 2019) with (2) no protein or PTM level enrichment technologies used, (3) with the existing state-of-the-art informatics solution at the time (a popular informatics sofware on a cluster) unable to separate the study conditions and (4) most importantly, with a difficult-to-separate set of study conditions (i.e., all the patients who entered the clinic had similar phenotypic profiles.)